Cargando…
Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549394/ https://www.ncbi.nlm.nih.gov/pubmed/33062268 http://dx.doi.org/10.3892/mco.2020.2148 |
| _version_ | 1783592785642782720 |
|---|---|
| author | Miyata, Yasuyoshi Araki, Kyohei Ohba, Kojiro Mastuo, Tomhiro Nakamura, Yuichiro Yuno, Tsutomu Mukai, Yuta Otsubo, Asato Mitsunari, Kensuke Mochizuki, Yasushi Sakai, Hideki |
| author_facet | Miyata, Yasuyoshi Araki, Kyohei Ohba, Kojiro Mastuo, Tomhiro Nakamura, Yuichiro Yuno, Tsutomu Mukai, Yuta Otsubo, Asato Mitsunari, Kensuke Mochizuki, Yasushi Sakai, Hideki |
| author_sort | Miyata, Yasuyoshi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7549394 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | D.A. Spandidos |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75493942020-10-14 Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial Miyata, Yasuyoshi Araki, Kyohei Ohba, Kojiro Mastuo, Tomhiro Nakamura, Yuichiro Yuno, Tsutomu Mukai, Yuta Otsubo, Asato Mitsunari, Kensuke Mochizuki, Yasushi Sakai, Hideki Mol Clin Oncol Corrigendum D.A. Spandidos 2020-12 2020-09-25 /pmc/articles/PMC7549394/ /pubmed/33062268 http://dx.doi.org/10.3892/mco.2020.2148 Text en Copyright: © Miyata et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
| spellingShingle | Corrigendum Miyata, Yasuyoshi Araki, Kyohei Ohba, Kojiro Mastuo, Tomhiro Nakamura, Yuichiro Yuno, Tsutomu Mukai, Yuta Otsubo, Asato Mitsunari, Kensuke Mochizuki, Yasushi Sakai, Hideki Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial |
| title | Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial |
| title_full | Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial |
| title_fullStr | Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial |
| title_full_unstemmed | Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial |
| title_short | Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial |
| title_sort | oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating tnf-α and tgf-β in renal cell carcinoma: a preliminary study based on a randomized double-blind clinical trial |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549394/ https://www.ncbi.nlm.nih.gov/pubmed/33062268 http://dx.doi.org/10.3892/mco.2020.2148 |
| work_keys_str_mv | AT miyatayasuyoshi oralintakeofroyaljellyimprovesanticancereffectsandsuppressesadverseeventsofmoleculartargetedtherapybyregulatingtnfaandtgfbinrenalcellcarcinomaapreliminarystudybasedonarandomizeddoubleblindclinicaltrial AT arakikyohei oralintakeofroyaljellyimprovesanticancereffectsandsuppressesadverseeventsofmoleculartargetedtherapybyregulatingtnfaandtgfbinrenalcellcarcinomaapreliminarystudybasedonarandomizeddoubleblindclinicaltrial AT ohbakojiro oralintakeofroyaljellyimprovesanticancereffectsandsuppressesadverseeventsofmoleculartargetedtherapybyregulatingtnfaandtgfbinrenalcellcarcinomaapreliminarystudybasedonarandomizeddoubleblindclinicaltrial AT mastuotomhiro oralintakeofroyaljellyimprovesanticancereffectsandsuppressesadverseeventsofmoleculartargetedtherapybyregulatingtnfaandtgfbinrenalcellcarcinomaapreliminarystudybasedonarandomizeddoubleblindclinicaltrial AT nakamurayuichiro oralintakeofroyaljellyimprovesanticancereffectsandsuppressesadverseeventsofmoleculartargetedtherapybyregulatingtnfaandtgfbinrenalcellcarcinomaapreliminarystudybasedonarandomizeddoubleblindclinicaltrial AT yunotsutomu oralintakeofroyaljellyimprovesanticancereffectsandsuppressesadverseeventsofmoleculartargetedtherapybyregulatingtnfaandtgfbinrenalcellcarcinomaapreliminarystudybasedonarandomizeddoubleblindclinicaltrial AT mukaiyuta oralintakeofroyaljellyimprovesanticancereffectsandsuppressesadverseeventsofmoleculartargetedtherapybyregulatingtnfaandtgfbinrenalcellcarcinomaapreliminarystudybasedonarandomizeddoubleblindclinicaltrial AT otsuboasato oralintakeofroyaljellyimprovesanticancereffectsandsuppressesadverseeventsofmoleculartargetedtherapybyregulatingtnfaandtgfbinrenalcellcarcinomaapreliminarystudybasedonarandomizeddoubleblindclinicaltrial AT mitsunarikensuke oralintakeofroyaljellyimprovesanticancereffectsandsuppressesadverseeventsofmoleculartargetedtherapybyregulatingtnfaandtgfbinrenalcellcarcinomaapreliminarystudybasedonarandomizeddoubleblindclinicaltrial AT mochizukiyasushi oralintakeofroyaljellyimprovesanticancereffectsandsuppressesadverseeventsofmoleculartargetedtherapybyregulatingtnfaandtgfbinrenalcellcarcinomaapreliminarystudybasedonarandomizeddoubleblindclinicaltrial AT sakaihideki oralintakeofroyaljellyimprovesanticancereffectsandsuppressesadverseeventsofmoleculartargetedtherapybyregulatingtnfaandtgfbinrenalcellcarcinomaapreliminarystudybasedonarandomizeddoubleblindclinicaltrial |